FDA okays ViiV's Apretude as first injectable for HIV PrEP

GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrE

Digital pill tracks HIV PrEP adherence with 98% accuracy

A digital pill that records when it is taken has been shown to be highly effective at helping patients adhere to pre-exposure prophylaxis (PrEP) treatment used to protect them from contract

Humira tops list of drugs with unwarranted US price hikes

Gilead will challenge US government patent on PrEP drug Truv...

Gilead files Truvada follow-up Descovy for PrEP

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six m

Charity raises funds for legal fight over HIV drug

National AIDS Trust continues legal battle over Truvada.